

From: [REDACTED] (GROW)
To: [REDACTED] @febea.fr"
Cc: [REDACTED] (GROW)
Subject: Ares(2019)291178 - RE: Cannabis / Cannabiol in cosmetic products
Date: vendredi 18 janvier 2019 14:11:07
Attachments: [image001.png](#)

Dear Ms. [REDACTED],

Thank you for your email.

We would like to inform you that currently, there are internal discussions and we hope to provide clarifications on the issue to the Working Group members via CIRCABC.

Please note that the minutes of the meeting will be available publicly in due course.

Kind regards

[REDACTED], PhD
[REDACTED]



European Commission

DG for Internal Market, Industry, Entrepreneurship and SMEs
Unit D4 – Health Technology and Cosmetics

BREY [REDACTED]
B-1049 Brussels/Belgium
Phone: +32 [REDACTED]
E-mail: [REDACTED] @ec.europa.eu
Website: [Cosmetics & Medical Devices](#)

Follow us on

Facebook: [EU Growth](#)

Twitter: [@EU_Growth](#)

Our Websites: [ec.europa.eu/growth](#)

[ec.europa.eu/bienkowska](#)

From: [REDACTED] <[REDACTED]@febea.fr>
Sent: Thursday, January 17, 2019 5:47 PM
To: [REDACTED] (GROW) <[REDACTED]@ec.europa.eu>
Cc: [REDACTED] <[REDACTED]@febea.fr>
Subject: Cannabis / Cannabiol in cosmetic products

Dear M. [REDACTED]

At the Cosmetic ad hoc working group of December 2018, the use of cannabis/cannabidiol in cosmetic products has been discussed.

A position by the Cosmetic Unit on the use of Cannabis/Cannabidiol (CBD) in cosmetic products issued in summer 2017 was mentioned by Danemark. FEBEA is very interested in receiving this position. Please could you send to us ?

Furthermore, is it possible to receive your last information on the status of cannabis in cosmetic product (december 2018).

Kinds regards.

